CNR1 and diabetes mellitus: Our final goal was to determine if nabilone, a synthetic commercially available cannabinoid with CB1 and CB2 agonism activity was beneficial in the diabetic peripheral neuropathy state and could prevent the development of neuropathic pain in this chronic disease state.